Cargando…

New rapid, accurate T(2) quantification detects pathology in normal-appearing brain regions of relapsing-remitting MS patients

INTRODUCTION: Quantitative T(2) mapping may provide an objective biomarker for occult nervous tissue pathology in relapsing-remitting multiple sclerosis (RRMS). We applied a novel echo modulation curve (EMC) algorithm to identify T(2) changes in normal-appearing brain regions of subjects with RRMS (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shepherd, Timothy M., Kirov, Ivan I., Charlson, Erik, Bruno, Mary, Babb, James, Sodickson, Daniel K., Ben-Eliezer, Noam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318543/ https://www.ncbi.nlm.nih.gov/pubmed/28239545 http://dx.doi.org/10.1016/j.nicl.2017.01.029

Ejemplares similares

Blood-Brain Barrier Permeability of Normal Appearing White Matter in Relapsing-Remitting Multiple Sclerosis
por: Lund, Henrik, et al.
Publicado: (2013)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Episodic Past, Future, and counterfactual thinking in Relapsing-Remitting Multiple sclerosis
por: Ayala, Oscar Daniel, et al.
Publicado: (2022)

Diffusion Tensor Imaging Revealed Microstructural Changes in Normal-Appearing White Matter Regions in Relapsing–Remitting Multiple Sclerosis
por: Bao, Jianfeng, et al.
Publicado: (2022)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Pilot study of a ketogenic diet in relapsing-remitting MS
por: Brenton, J. Nicholas, et al.
Publicado: (2019)

Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients()
por: Graziano, Elliot, et al.
Publicado: (2015)

Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis
por: Gschwind, Markus, et al.
Publicado: (2016)

Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy
por: Ruiz-Peña, Juan Luis, et al.
Publicado: (2004)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS
por: Najafi, Behzad, et al.
Publicado: (2015)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)
por: Camu, William, et al.
Publicado: (2019)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
por: Nash, Richard A., et al.
Publicado: (2017)

Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability
por: Has Silemek, Arzu Ceylan, et al.
Publicado: (2020)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Sips, Fianne L. P., et al.
Publicado: (2022)

The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing–remitting multiple sclerosis
por: Caligiuri, Maria Eugenia, et al.
Publicado: (2014)

Functional connectivity dynamics reflect disability and multi-domain clinical impairment in patients with relapsing-remitting multiple sclerosis
por: Romanello, Amy, et al.
Publicado: (2022)

Metabolic Insights into Iron Deposition in Relapsing-Remitting Multiple Sclerosis via 7 T Magnetic Resonance Spectroscopic Imaging
por: Lipka, Alexandra, et al.
Publicado: (2023)

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod
por: Kihara, Yasuyuki, et al.
Publicado: (2022)

Characterization of relapsing-remitting multiple sclerosis patients using support vector machine classifications of functional and diffusion MRI data
por: Zurita, Mariana, et al.
Publicado: (2018)

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?
por: Marrie, Ruth Ann
Publicado: (2017)

Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodies
por: Foulon, North, et al.
Publicado: (2022)

An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
por: Habler, Katharina, et al.
Publicado: (2022)

FLAIR MRI biomarkers of the normal appearing brain matter are related to cognition()
por: Bahsoun, M-A., et al.
Publicado: (2022)

A tractometry principal component analysis of white matter tract network structure and relationships with cognitive function in relapsing-remitting multiple sclerosis
por: Jandric, Danka, et al.
Publicado: (2022)

Longitudinal microstructural MRI markers of demyelination and neurodegeneration in early relapsing-remitting multiple sclerosis: Magnetisation transfer, water diffusion and g-ratio
por: York, Elizabeth N., et al.
Publicado: (2022)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
por: Tao, Yazhong, et al.
Publicado: (2015)

Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS
por: Sriram, Subramaniam, et al.
Publicado: (2018)

White matter hyperintensities and normal-appearing white matter integrity in the aging brain
por: Maniega, Susana Muñoz, et al.
Publicado: (2015)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis
por: Cassiano, Maria Teresa, et al.
Publicado: (2020)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
por: Barrero, Francisco, et al.
Publicado: (2020)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
por: Limmroth, Volker, et al.
Publicado: (2014)

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS
por: Stellmann, Jan‐Patrick, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_86dkgnnfpai6f5818bv9918fmq